News Release

Cure Mito Foundation, a parent-led nonprofit dedicated to advancing research and treatments for Leigh syndrome, announces a formation of a Corporate Advisory Council

Business Announcement

Cure Mito Foundation

McKinney, TX., January 23, 2023 — Cure Mito Foundation, in collaboration with five of the industry’s prominent rare disease companies - PTC Therapeutics, Astellas, Saol Therapeutics, Standigm, and Abliva, today announced the launch of a unique Corporate Advisory Council (CAC).

The CAC’s goal is to unite mitochondrial disease stakeholders across different organizations with a common goal to accelerate the development and delivery of treatments, and ultimately a cure, for Leigh syndrome and mitochondrial disease.  CAC members will have a seat around the table within the patient advocacy community while raising awareness and visibility of its companies and their programs.

"We feel very lucky to have the chance to serve as a corporate member of the Cure Mito advisory council in 2023. Developing STE-2502076, an AI-discovered repurposed drug for mitochondrial disease, we have admired the dedication of Cure Mito to building a patient-centered research network,” said Jinhan Kim, co-founder, and CEO of Standigm. “We believe we can meet more mito people such as patients, caretakers, researchers and other industry experts, and this network of Cure Mito leads us to successful IND (Investigational new drug) application as well."  

Kasey Woleben, Cure Mito co-founder and a mom to Will, who has Leigh syndrome, said: “As a foundation led by affected families, we understand the true impact of the disease and the urgency that is required in driving research and treatments forward. By forming this Corporate Advisory Council, we will be able to discuss and address challenges facing the mitochondrial disease community together, align different stakeholders, and collaboratively be able to help our patient community faster and more efficiently. We couldn't be more grateful to the companies who have stepped up to drive this very important effort with us.”

Those who want to learn more or join the CAC are encouraged to reach out to


About The Cure Mito Foundation

Cure Mito Foundation is a parent-led 501(c)(3) nonprofit organization that was founded in 2018 as a Cure SURF1 Foundation by a group of families determined to fight for their children’s lives. In 2021, after successfully blazing the trail for SURF1 gene therapy at the University of Texas Southwestern Medical Center, the mission of the organization expanded and the name was amended.  Cure Mito’s focus  is to unite  the global Leigh syndrome community to accelerate patient-centered research, treatments, and cures. Cure Mito is an all-volunteer organization, which allows 100% of donations to go to research. Cure Mito has an international reach with patients from over 30 countries, currently a part of the Leigh syndrome global patient registry that Cure Mito has developed.  Cure Mito is a member of COMBINEDBrain, Global Genes Foundation Alliance, Everylife Foundation Community Congress, and Indo US Rare Organization for Rare Diseases.  For more information please visit: or follow us on ​LinkedIn | Twitter | Facebook | Instagram.


About PTC Therapeutics

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.


About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at


About Saol Therapeutics

Saol Therapeutics (pronounced "Sail") is a privately held, clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland and Hamilton, Bermuda.  Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases.  Saol is committed to providing and advancing therapeutic options for patients and the physicians treating these populations.  For more information, visit


About Standigm

Standigm is a workflow AI-driven drug discovery company with offices in Cambridge, UK, Cambridge, MA, USA, and Seoul, South Korea.   Standigm has proprietary AI platforms encompassing novel target identification to compound design, to generate commercially valuable drug pipelines. Founded in 2015 in Seoul, South Korea, Standigm has established an early-stage drug discovery workflow AI to generate multiple first-in-class compounds in an average of seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for novel target discovery and Standigm BEST™ for novel compound generation. Learn more at


About Abliva

Abliva discovers and develops medicines for the treatment of primary mitochondrial diseases. These rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI). For more information, please visit





Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.